• 1
    Feng S, Buell JF, Chari RS, DiMaio JM, Hanto DW. Tumors and Transplantation: The 2003 Third Annual ASTS State-of-Art Winter Symposium. Am J Transplant 2003; 3: 14811487.
  • 2
    Kasiske BL, Snyder JJ, Gilbertson DT, Wang C. Cancer after kidney transplantation in the United States. Am J Transplant 2004; 4: 905913.
  • 3
    Thorley-Lawson DA, Gross A. Persistence of the Epstein-Barr virus and the origins of associated lymphomas. NEJM 2004; 350: 13281337.
  • 4
    Hanto DW. Classification of Epstein-Barr virus associated posttransplant lymphoproliferative diseases: Implications for understanding their pathogenesis and developing rational treatment strategies. Annu Rev Med 1995; 46: 381394.
  • 5
    Paya CV, Fung JJ, Nalesnik MA et al. Epstein-Barr virus induced posttransplant lymphoproliferative disorders. Transplantation 1999; 68: 15171525.
  • 6
    Cherikh WS, Kauffman HM, McBride MA, Maghirang, Swinnen LJ, Hanto DW. Association of the type of induction immunosuppression with posttransplant lymphoproliferative disorder, graft survival, and patient survival after primary kidney transplantation. Transplantation 2003; 76: 12891293.
  • 7
    Hanto DW, Birkenbach M, Frizzera G, Gajl-Peczalska, Simmons RL, Schubach WH. Confirmation of the heterogeneity of posttransplant Epstein-Barr virus associated B cell proliferations by immunoglobulin gene rearrangement analyses. Transplantation 1989; 47: 458464.
  • 8
    McDiarmid SV, Jordan S, Lee GS et al. Prevention and preemptive therapy of posttransplant lymphoproliferative disease in pediatric liver recipients. Transplantation 1998; 66: 16041611.